The Pieces Are Now Falling into Place in Ovarian Cancer Surgery

In advanced ovarian cancer, extensive removal of neighboring lymph nodes in addition to the primary tumor did not improve survival but caused more adverse effects, as shown on 28 February 2019 in NEJM by the published LION clinical trial.
A video summary of the LION study is below:
For advanced ovarian cancers, the main treatment is surgery aiming to remove all visible tumors completely—called macroscopic R0 resection—followed by carboplatin-paclitaxel chemotherapy.
The most important determinant of surgical outcomes in ovarian cancer is how much tumor remains after surgery. If no macroscopically visible tumor remains, it is considered completely removed. Lymphatic vessels are a route of spread common to both early and advanced ovarian cancer and an important factor in predicting disease course. Studies to date have found lymph node metastases during surgery in % 44 - 53 of patients. Some retrospective (backward-looking) data suggest that extensive removal of pelvic and paraaortic nodes around the ovaries improves survival, but no prospective (forward-looking) randomized trial had demonstrated this benefit. The Lymphadenectomy in Ovarian Neoplasms (LION) study was conducted for this purpose.
Study Method
Patients with ovarian cancer from stage IIB through stage 4, normal lymph nodes before and during surgery, and macroscopically complete tumor removal were enrolled, totaling 647 patients. Enrolled between 2008 and 2012, participants were randomized to lymphadenectomy (323 patients) or no lymphadenectomy (324 patients). All participating centers were assessed before the study regarding oncological surgery to ensure that they met quality standards. The study’s primary endpoint was defined as overall survival.
Results of the LION Study
- Patients undergoing lymphadenectomy had a median of 57 lymph nodes removed (35 pelvic and 22 paraaortic nodes).
- Comparing median overall survival, patients undergoing lymphadenectomy had 65.5 months, while those without lymph node removal had 69.2 months.
- Median progression-free survival was 25.5 months in both groups.
- Serious postoperative adverse effects were significantly more frequent in the lymphadenectomy group (%12.4 versus %6.5).
- Mortality (death) within the first 60 days after surgery was %3.1 with lymphadenectomy and %0.9 without it.
In conclusion, in patients with advanced ovarian cancer whose tumor was completely removed and whose lymph nodes were normal before and during surgery, systematic pelvic and paraaortic lymphadenectomy improved neither overall nor progression-free survival. It also caused more postoperative adverse effects.
Sources
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.
NEJM, 28 February 2019
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.